Business Context and Reporting Period
This Form 8-K filing by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reports a significant executive leadership change. The report date is November 21, 2025, with the document signed on November 28, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and the associated compensation terms.
Material Changes
- Departure of CFO: Timothy Lorber resigned as Chief Financial Officer effective immediately on November 21, 2025.
- Interim Appointment: Christopher Cooper, currently serving as Interim Chief Executive Officer, assumed the role of Chief Financial Officer (Principal Financial Officer) effective November 21, 2025, pending a search for a permanent replacement.
- Compensation Arrangement: A Separation Agreement and Mutual Release was executed with Mr. Lorber.
Guidance, Outlook, and Unusual Items
The filing details the specific terms of the separation agreement for the departing CFO, which include:
- Transition Services: Mr. Lorber will provide part-time services at 50% of his base salary through December 4, 2025, and remain available for consultation through February 8, 2026.
- Retention Bonuses: A total of $30,000 in bonuses ($20,000 on November 21, 2025, and $10,000 on December 4, 2025).
- Equity Vesting: Accelerated vesting of 39,854 unvested restricted stock units on February 8, 2026, contingent upon fulfilling the transition plan.
- Legal Terms: The agreement includes a mutual release of claims, confidentiality, non-disparagement, and cooperation provisions.
The filing does not provide updated financial guidance or discuss operational risks beyond the transition of duties.
Investor Verification Checklist
- Verify the timeline for the search and appointment of a permanent Chief Financial Officer.
- Review the full Separation Agreement (Exhibit 10.1) for any additional covenants or exclusions not summarized in the text.
- Monitor future filings for the impact of the CFO transition on financial reporting timelines or internal controls.
- Confirm the status of the 39,854 restricted stock units and their potential impact on share count upon vesting in February 2026.